Neurology · Pain ManagementRegulatory Approvalregulatorymid-term

Aurobindo Pharma submits supplemental ANDA for Pregabalin

Importance6/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Aurobindo Pharma7 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/27/2026, 6:05:26 AM

Assessment confidence: 51% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

Aurobindo Pharma's submission of a supplemental ANDA for Pregabalin is significant as it may intensify competition in the generic market. Portfolio teams should evaluate the potential impact on pricing and market share dynamics in the neurology and pain management therapeutic areas. Regulatory context from FDA (FDA AP — PREGABALIN (SUPPL)) supports the near-term read. Assessment grounded in 8 ranked evidence items (2 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this submission on market share and pricing strategies for pregabalin products. The strongest clinical anchor is Evaluation of the Japet.W+ Medical Device for Low Back Pain Management (ClinicalTrials.gov), sub-indication match (pain). In pain, 5 regulatory and 1 competitive items passed relevance filtering for Aurobindo Pharma.

Competitive Pressure

The most relevant competitive pressure comes from FDA Approval for Oxycodone Hydrochloride by Novel Labs (Humanexa Signals) — sub-indication match (pain). This submission may enhance Aurobindo's position in the generic pregabalin market, potentially increasing competition against existing players.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — PREGABALIN (SUPPL) (FDA). Entity match (aurobindo pharma); Regulatory pathway relevance (nda). The FDA's review process will determine the approval timeline and any changes to the competitive landscape, which could influence compliance and market entry strategies.

Key Risks

Elevated medium regulatory exposure for Aurobindo Pharma could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Increased competition could lead to pricing pressures, affecting revenue for existing players in the pregabalin market. Companies may need to adjust their strategies to maintain market share.
Portfolio teams should assess the impact of this submission on market share and pricing strategies for pregabalin products.

What Would Change This Assessment

This becomes more urgent if Monitor the FDA's review timeline and any subsequent approval announcements.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — PREGABALIN (SUPPL)
FDAmedium relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PREGABALIN (ORIG)
FDAmedium relevance
Entity match (pregabalin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source
Report on the State of Pharmaceutical Quality
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Evaluation of the Japet.W+ Medical Device for Low Back Pain Management
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Human Experimental Models of Pain (HEMP)
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Effects of Music Therapy in Chronic Neck Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Pelvic Pain in Women With Endometriosis
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Study Title: A Multicenter, Prospective, Modified Platform Trial Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects Of Sahrmann's Versus McGill Exercise In Patients With Non-Specific Low Back Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Comparative Outcomes of Inj Botox Alone vs Inj Botox Combined With Fissurectomy and Anoplasty in the Management of Chronic Anal Fissure
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Approval for Oxycodone Hydrochloride by Novel Labs
Humanexa Signalsmedium relevance
Sub-indication match (pain)
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalslow relevance
Sponsor/company relevance (Roche)
FDA Approves Supplemental Application for Copaxone (Glatiramer Acetate)
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities
FDA Accepts Supplemental BLA for OCREVUS ZUNOVO by Genentech
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Lavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Factors predicting health-enhancing physical activity in patients with chronic widespread pain following a person-centred health plan.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Aurobindo Pharma
Pregabalin

Commercial impact

medium

Increased competition could lead to pricing pressures, affecting revenue for existing players in the pregabalin market. Companies may need to adjust their strategies to maintain market share.

Regulatory impact

medium

The FDA's review process will determine the approval timeline and any changes to the competitive landscape, which could influence compliance and market entry strategies.

What to watch

Monitor the FDA's review timeline and any subsequent approval announcements.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.